AHCLNSEAnlon Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 9 Feb, 2026 · 15:14 IST

Anlon Healthcare Q3 FY26: revenue falls 50% YoY, CFO and Director changes

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.7%Reaction day
₹12.77
prior close
₹12.50
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+2.6%-3.3% vs market
Pharmaceuticals peers, median of 159sector+1.8%-2.6% vs sector

On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.8
10m
+1.8
15m
+1.4
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.7+2.6-3.3+1.8-2.6
Next day
-3.1+3.6-6.7+2.4-5.5
2d
-3.7+3.1-6.8+2.0-5.7
3d
-4.6+2.6-7.2+1.3-5.9
4d
-5.2+1.1-6.3+0.7-6.0
5d
-5.5+0.3-5.8+0.0-5.5
1w
-4.5+1.6-6.1+0.8-5.3
15d
-13.2-3.9-9.2-4.3-8.9
1m
-2.1-8.1+6.0-5.3+3.1
2m
-4.1-3.1-1.0-2.9-1.2
3m
+11.2+9.2+2.0+4.6+6.6
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anlon Healthcare Q3 FY26 revenue was Rs 35.6 crore, down 50% YoY from Rs 71.4 crore. 9M FY26 revenue was nearly flat at Rs 121 crore. Q3 PAT dropped to Rs 5.15 crore from Rs 9.32 crore; 9M PAT was Rs 18 crore versus Rs 20.5 crore. CFO Hitesh Makwana resigned citing pre-occupation, replaced by Naimish Bhatt. Independent Director Shailesh Thakkar quit for health reasons, replaced by Kishan Raja. IPO funds of Rs 121 crore used as planned.

Likely market impact

Sharp Q3 revenue drop raises concern; 9M stable. New CFO and Independent Director appointed; IPO funds deployed on plan.